136 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 136 of 136 clinical reviews.
A clinical guide to monitoring suvorexant (Belsomra) in adolescents aged 12 to 17, covering dosing, sleep-architecture effects, mental-health surveillance, growth considerations, and when to discontinue.
Evidence-based guide to suvorexant (Belsomra) dosing in adolescents aged 12-17, including FDA labeling gaps, off-label considerations, safety data, and mental-health monitoring.
Current Belsomra prices in Alabama for 2026, including cash-pay costs, Alabama Medicaid coverage status, insurance options, the Merck savings card, and compounded suvorexant availability through 503A pharmacies.
Current Belsomra pricing in Alaska for 2026, including cash-pay costs, Alaska Medicaid coverage status, insurance options, compounded suvorexant availability, and discount programs.
Current Belsomra prices in Arizona for 2026, including cash-pay costs, Medicaid coverage status, insurance options, compounded suvorexant availability, and discount programs.
Current Belsomra (suvorexant) prices in Arkansas for 2026, including cash-pay costs, Medicaid PA requirements, insurance coverage, manufacturer savings cards, and compounded alternatives.
What Belsomra costs in California in 2026, including cash prices, Medi-Cal coverage, insurance options, compounded suvorexant, and discount programs.
What Belsomra costs in Colorado in 2026, including cash prices, Medicaid coverage, insurance options, manufacturer savings cards, and compounded suvorexant availability through 503A pharmacies.
Current Belsomra pricing in Connecticut for 2026, including cash-pay costs, Medicaid coverage with prior authorization, insurance options, the Merck savings card, and compounded suvorexant availability through 503A pharmacies.
Current Belsomra (suvorexant) prices in Delaware for 2026, including cash-pay costs, Medicaid coverage, insurance options, the Merck savings card, and compounded alternatives.
Current Belsomra (suvorexant) prices in District of Columbia for 2026. Covers Medicaid PA requirements, insurance tiers, the Merck savings card, compounded suvorexant from 503A pharmacies, and telehealth access in DC.
Current Belsomra (suvorexant) pricing in Florida for 2026, including cash-pay costs, Medicaid coverage status, insurance options, compounded alternatives, and discount programs.
Current Belsomra (suvorexant) prices in Iowa for 2026, including cash-pay costs, Iowa Medicaid coverage status, insurance options, discount programs, and compounded alternatives.
Current Belsomra (suvorexant) pricing in Kansas for 2026, including cash-pay costs, Kansas Medicaid coverage details, insurance options, manufacturer savings cards, and compounded alternatives.
Current Belsomra pricing in Kentucky for 2026, including cash-pay costs, Medicaid coverage status, insurance options, manufacturer savings cards, and compounded suvorexant availability through 503A pharmacies.
Current Belsomra prices in Louisiana for 2026, including cash-pay costs, Medicaid coverage status, insurance options, telehealth access, and discount programs for suvorexant.
What Belsomra (suvorexant) costs in Maine in 2026, including cash prices, Medicaid PA requirements, insurance tiers, compounded alternatives, and every discount program available to Maine residents.
What Belsomra costs in Massachusetts in 2026, including cash prices, Medicaid coverage, insurance options, the Merck savings card, and compounded suvorexant availability.
Current Belsomra (suvorexant) pricing in Michigan for 2026, including cash-pay costs, Medicaid coverage, insurance options, the Merck savings card, and compounded alternatives.
Current Belsomra pricing in Minnesota for 2026, including cash-pay costs, Medicaid coverage with prior authorization, insurance options, telehealth access, and manufacturer savings programs.
Current Belsomra (suvorexant) prices in Mississippi for 2026, including cash-pay costs, Medicaid coverage status, insurance options, the Merck savings card, and compounded alternatives through 503A pharmacies.
Current Belsomra (suvorexant) pricing in Nebraska for 2026, including cash-pay costs, Nebraska Medicaid status, insurance coverage, manufacturer savings cards, and compounded alternatives.
Current Belsomra (suvorexant) pricing in Nevada for 2026, including cash-pay costs, Medicaid coverage status, insurance options, compounded alternatives, and discount programs.
Current Belsomra (suvorexant) pricing in New Hampshire for 2026, including cash-pay costs, Medicaid coverage status, insurance options, telehealth access, and discount programs.
Current Belsomra prices in New Mexico for 2026. Compare cash-pay, insurance, Medicaid, telehealth, and discount options for suvorexant across NM pharmacies.
What Belsomra costs in North Carolina in 2026, including cash prices, Medicaid coverage status, insurance options, manufacturer savings cards, and compounded suvorexant availability through 503A pharmacies.
Current Belsomra prices in North Dakota for 2026, including cash-pay costs, Medicaid status, insurance coverage, manufacturer savings cards, and compounded suvorexant options.
What Belsomra costs in Ohio in 2026, including cash prices, Ohio Medicaid coverage status, insurance options, the Merck savings card, and compounded suvorexant availability through 503A pharmacies.
Current Belsomra prices in Oklahoma for 2026, including cash-pay costs, Medicaid coverage status, insurance options, telehealth access, and compounded suvorexant availability through 503A pharmacies.
What Belsomra costs in Oregon in 2026, including cash prices, Oregon Medicaid coverage with prior authorization, Merck savings cards, compounded suvorexant from 503A pharmacies, and telehealth options.
Current Belsomra (suvorexant) prices in Pennsylvania for 2026, including cash-pay costs, Medicaid coverage, insurance options, the Merck savings card, and compounded suvorexant availability.
Current Belsomra prices in Rhode Island for 2026, including cash-pay costs, Medicaid PA requirements, insurance coverage details, compounded suvorexant options, and manufacturer savings programs.
What Belsomra (suvorexant) costs in South Carolina in 2026, including cash prices, Medicaid coverage, insurance options, the Merck savings card, compounded alternatives, and telehealth access.
Current Belsomra pricing in South Dakota for 2026, including cash-pay costs, Medicaid coverage status, insurance options, telehealth access, and discount programs.
What Belsomra costs in Utah in 2026, including cash prices, Medicaid coverage, insurance options, compounded suvorexant, telehealth access, and discount programs.
What Belsomra (suvorexant) costs in Virginia in 2026, including cash prices, Medicaid coverage, insurance options, the Merck savings card, compounded alternatives, and telehealth access.
What Belsomra costs in West Virginia in 2026, including cash prices, Medicaid coverage status, insurance options, the Merck savings card, compounded suvorexant, and telehealth access.
Current Belsomra (suvorexant) pricing in Wisconsin for 2026, including cash-pay costs, Medicaid PA requirements, insurance coverage, manufacturer savings cards, and compounded alternatives.
What Belsomra costs in Wyoming in 2026, including cash prices, Medicaid coverage status, insurance options, manufacturer savings cards, and compounded suvorexant availability.
Evidence-based guide to suvorexant (Belsomra) dosing in adults ages 50 to 64, covering starting doses, titration, drug interactions, and perimenopause/andropause considerations reviewed by the HealthRX medical team.
Complete dosing guide for suvorexant (Belsomra) in adults aged 18, 29, including starting dose, titration, drug interactions, fertility considerations, and clinical trial data reviewed by HealthRX.com physicians.
Evidence-based guide to suvorexant (Belsomra) dosing in patients with kidney disease. No dose adjustment is needed for renal impairment, but clinical nuance matters. FDA label, pharmacokinetic data, and practical guidance.
Evidence-based guide to suvorexant (Belsomra) dosing in older adults aged 65+. Covers starting dose, titration, fall risk, drug interactions, and deprescribing for geriatric insomnia.
A detailed history of suvorexant (Belsomra), the first dual orexin receptor antagonist approved for insomnia, covering orexin science, Merck's clinical development program, FDA review, and the drug's place in sleep medicine.
Evidence-based review of suvorexant (Belsomra) safety during pregnancy and breastfeeding, including FDA labeling, animal data, human evidence gaps, and safer insomnia alternatives for expectant and nursing mothers.
A clinician-level review of suvorexant (Belsomra) use in transplant recipients, people living with HIV, hepatic impairment, elderly patients, and other complex populations. Covers mechanism, drug interactions, dosing adjustments, and trial evidence.
A clinical review of Belsomra (suvorexant) manufacturing by Merck, FDA supply chain records, shortage history, and the drug's dual orexin receptor antagonist mechanism of action.
Evidence-based monitoring guide for adults aged 30, 49 taking Belsomra (suvorexant) for insomnia, covering baseline labs, follow-up timing, side-effect tracking, and when to adjust therapy.
Evidence-based monitoring guide for suvorexant (Belsomra) in adults aged 50 to 64, covering liver function, CNS effects, drug interactions, sleep diaries, and when to adjust or discontinue therapy.
A clinical guide to monitoring suvorexant (Belsomra) in young adults ages 18 to 29, covering safety checkpoints, fertility considerations, next-day impairment, dependence risk, and when to reassess therapy.
Clinical guide to suvorexant (Belsomra) overdose management, including signs of excess dosing, treatment protocols, pharmacology, and when to seek emergency care.
Evidence-based guide to monitoring suvorexant (Belsomra) use in pediatric patients under 12, including safety parameters, growth tracking, and off-label prescribing considerations.
Complete regulatory overview of suvorexant (Belsomra) across the US, EU, Canada, and UK, including FDA approval history, EMA status, mechanism of action, and prescribing classifications.
A clinician-reviewed guide to suvorexant (Belsomra) safety for adults aged 50 to 64, covering orexin mechanism, trial data, drug interactions, perimenopause and andropause considerations, and dosing guidance.
A clinician-reviewed guide to suvorexant (Belsomra) safety in young adults ages 18 to 29, covering trial evidence, dosing, fertility considerations, drug interactions, and how orexin antagonism differs from older sleep aids.
Clinical evidence, FDA status, dosing considerations, and mental-health monitoring for suvorexant (Belsomra) use in adolescents aged 12 to 17.
Evidence-based review of suvorexant (Belsomra) safety in geriatric patients, covering falls, next-day sedation, drug interactions, dosing, and deprescribing.
Evidence-based safety profile of suvorexant (Belsomra) for insomnia in adults aged 30 to 49, including side effects, drug interactions, next-day impairment, and clinical trial data.
A clinician-reviewed guide to suvorexant (Belsomra) safety in pediatric patients under age 12, covering FDA labeling, pharmacology, adverse-effect profiles, and when off-label use may be considered.
An evidence-based review of Belsomra safety, FDA labeling, complex sleep behaviors, next-day impairment, CYP3A interactions, and whether suvorexant has a boxed warning.
Showing the first 60 matches. Use search or filters to narrow the library.